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ABSTRACT
Introduction: Cardiovascular diseases (CVDs)
represent a major Public Health burden. High
serum cholesterol levels have been linked to
major CV risk. The objectives of this study
were to review the epidemiology of
hypercholesterolemia in high risk CV patients
from Spain, by assessing its prevalence, the
proportion of diagnosed patients undergoing
pharmacological treatment and the degree of
attained lipid control.
Methods: A systematic literature review was
carried out using Medline and two Spanish
databases. Manuscripts containing information
on hypercholesterolemia in several high CV risk
groups [diabetes mellitus (DM), Systematic
COronary Risk Evaluation (SCORE) risk [5, or
documented CVD], published between January
2010 and October 2014, were included.
Results: Of the 1947 published references
initially retrieved, a full-text review was done
on 264 manuscripts and 120 were finally
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included. Prevalence of hypercholesterolemia
ranged from 50 to 84% in diabetics, 30–60% in
patients with DM or elevated SCORE risk,
64–74% with coronary heart disease, 40–70%
in stroke patients, and 60–80% in those with
peripheral artery disease. Despite the finding
that most of them were on pharmacological
treatment, acceptable control of serum lipids
was very variable, ranging from 15% to 65%.
Among those with heterozygous familial
hypercholesterolemia, 95–100% received
treatment but less than 50% achieved their
therapeutic goals.
Conclusions: An elevated prevalence of
hypercholesterolemia can be found in targeted
groups at high CV risk. Although most patients
are receiving pharmacological treatment, rates
of lipid control continue to be low, both in
primary and secondary prevention.




The overall prevalence of hypercholesterolemia
in the Spanish adult population has been
estimated between 34% and 50% in recent
studies [1–3]. The importance of this high
prevalence is due to the association of high
levels of serum cholesterol with cardiovascular
disease (CVD), which has been well established
[4, 5]. For instance, the occurrence of CV events
in patients with familial hypercholesterolemia
has been highlighted, with a prevalence of
premature CVD (before 55 years of age in men
and before 65 years of age in women) of 10%, in
contrast to less than 3% in relatives without
familial hypercholesterolemia [6].
The therapeutic arsenal available for
hypercholesterolemia includes the standard
treatment based on lifestyle and dietary
modification strategies, and lipid-lowering
medications, mainly statins [7]. Other existing
treatments for controlling low-density
lipoprotein cholesterol (LDLc) levels are
ezetimibe (added to statins in primary
hypercholesterolemia and homozygous
familial hypercholesterolemia or as a
monotherapy in cases of statin intolerance or
if they are contraindicated), fibrates and
bile-acid sequestrants. In addition, newly
developed lipid-lowering drugs (monoclonal
antibodies proprotein convertase subtilisin/
kexin type 9 inhibitor) have been recently
approved by the Food and Drug
Administration and European Medicines
Agency. Lipid-lowering treatments (LLT) are
efficacious in reducing LDLc levels and
reducing the burden of major CV events as
well as CV mortality, even among populations
without known CVD [8, 9]. Consequently,
recent European Clinical Practice Guidelines
have established LDLc targets accordingly to
individual’s CV risk [7]: LDLc levels\100 mg/dl
for patients without CVD, but with diabetes
mellitus (DM) or with high CV risk based on a
Systematic COronary Risk Evaluation (SCORE)
risk assessment [5 (Primary prevention
hereinafter), and \70 mg/dl for patients with
overt CVD, i.e., those who have suffered a
previous CV event (Secondary prevention).
However, according to the results published in
a multinational study conducted between 2006
and 2007, despite the use of LLT, a significant
proportion of patients did not attain target
levels of LDLc [10], which means they still
have a significant CV residual risk.
Understanding the contemporary magnitude
of this condition is of importance to plan
additional interventions to reach LDLc targets
and to reduce the burden of the related CV
events and deaths. Thus, the objectives of the
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present research were to review the published
evidence addressing the prevalence of
hypercholesterolemia, the usual clinical
management of lipid profile, and the attained
control of LDLc levels in patients with high CV
risk from Spain.
METHODS
A systematic review of the literature was
conducted in accordance with the accepted
standards [11] and with a research question
defined with reference to Patients,
Interventions, Comparisons, Outcomes, and
Study design (PICOS) (please see Table S1 in
the supplementary material for details). The
search was run on the second week of October
2014 (from 6th to 10th) in Medline and two
Spanish electronic databases: Biblioteca Virtual
de la Salud (BVS) and Medes. The search
strategies included both controlled and free
terms in both English and Spanish languages.
The search strategies executed in each
electronic public-access libraries are presented
in Table S2 in the supplementary material.
The information gathered was manually
cross-checked using the relevant references
given in the publications included. To select
the studies, titles and abstracts were first
examined. After this, full text of selected
manuscripts was reviewed. The selection
criteria for publications were as follows:
Inclusion Criteria
Studies carried out in Spain and focused on lipid
levels of patients belonging to one of the
following groups: (a) heterozygous familial
hypercholesterolemia (HeFH); (b) overt CVD
including acute coronary syndrome (ACS),
chronic coronary heart disease (CHD),
ischemic stroke (IS) and peripheral arterial
disease (PAD); (c) DM; or (d) high CV risk.
ACS was defined as acute myocardial infarction
or unstable angina in the last 12 months.
Chronic CHD refers to patients with ACS
occurred longer than 12 months, or with
stable angina or revascularization. Regarding
CV risk, a SCORE risk assessment[5 (tables for
countries with low CV risk) or equivalent was
considered. Furthermore, according to the
objectives described before, the studies had to
include information on one of the following
results: (a) prevalence of hypercholesterolemia;
(b) rates of pharmacological treatment or
(c) control of LDLc levels.
Exclusion Criteria
Manuscripts were discarded if any of the
following conditions applied: (a) carried out
outside Spain; (b) studies that did not include
original patient data (i.e., reviews, editorials or
letters); (c) studies that did not include human
data; (d) studies with pediatric populations or
(e) case reports.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies, and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RESULTS
A total of 1362 publications were retrieved from
PubMed, 537 from the BVS and 560 from Medes
(512 were duplicates so an initial pool of 1947
original manuscripts were identified for title
and abstract review). Following the selection
process, the full text of 264 manuscripts was
reviewed, of which a total of 120 original papers
were finally considered (Fig. 1).
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HeFH
In the study using data from the electronic
database of the Spanish Familial
Hypercholesterolemia Longitudinal Cohort Study
(SAFEHEART) [12], 84% of the HeFH patients were
receiving LLT at the time of inclusion (97% index
cases and 78% HeFH relatives). 95% of treated
patients received statins, 58% as monotherapy and
31% in combination, mostly with ezetimibe.
Meanwhile, in another observational study [13]
which included 241 patients with HeFH and 286
with combined familial hypercholesterolemia,
100% received LLT during a monitoring period of
1 year. Patients took an average of 1.5
lipid-lowering drugs (94% statins and 33%
ezetimibe).
Despite the high proportion of patients
undergoing a LLT in both studies [12, 13],
between 72% and 96%, approximately, did not
reach a target LDLc below 100 mg/dl and only




In studies carried out among patients with ACS
the prevalence of hypercholesterolemia was
highly variable ranging from 45% to 80%
[15–31]. The proportion of ACS patients
undergoing LLT ranged between 33% and
90%, but control levels were poor with only
14% of patients with LDLc levels\70 mg/dl and
Fig. 1 Flow diagram showing the selection process of the included articles. BVS Biblioteca Virtual de la Salud
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56% meeting the target of LDLc \100 mg/dl
[26] (Table 2; Fig. 2).
CHD
The prevalence of hypercholesterolemia in
patients with chronic CHD was more uniform
than that found in patients with ACS, according
to the information collected, ranging from 64%
to 74% [32–38, 44–46]. More than 80% of
patients were receiving LLT, statins accounting
for 95% of them [37]. Again, despite the high
proportion of treatment, only between 26% and
55% of patients had LDLc levels \100 mg/dl
(Table 2).
IS
The prevalence of hypercholesterolemia in
patients with IS ranged from 40% to 70%
[39–41, 47–60]. The proportion of treated
patients was lower than that found in ACS or
CHD patients. Upon discharge from hospital
following an IS episode, between 38% and 76%
of patients were receiving LLT [39, 40, 49]. In
addition, one observational study with 203
patients admitted for medium- to long-term
stays in one hospital between 2009 and 2010
found that only 20% of the total number of
post-event patients received the dosage
recommended by current guidelines [54].
With regards to attained cholesterol levels, 3
studies were found [39–41], reporting figures on
LDLc control of\100 mg/dl between 25% and
33%. In two additional studies [54, 61] in which
targets were set at Total Cholesterol
(TC)\175 mg/dl, control rates were between
43% and 77% (Table 2; Fig. 2).
Table 1 Lipid-lowering treatments and LDL cholesterol targets in Heterozygous familial hypercholesterolemia
Study Study size Treatment Control
[12]a N = 1852 (1262 FH and 590
relatives non FH)
LLT: 83.7% (97% FH and 78%
relatives FH)
Statins monotherapy: 58.3%
Statin ? ezetimibe: 31.3%
LDLc\100 mg/dl: 33 (3.4%) of
FH on LLT
[13]b N = 527 (241 HeFH and 286
combined FH)




[14] 37 HeFH and 37 controls Statins: 100% HeFH and 100%
no-HeFH
Ezetimibe: 23 (62.2%) HeFH; 4
(10.8%) no-HeFH
LDLc\100 mg/dl: 11% of HeFH
LLT lipid-lowering treatment, FH familiar hypercholesterolemia, LDLc low-density lipoprotein cholesterol, HeFH
heterozygous familial hypercholesterolemia
a Only 13% received maximum daily statin doses, deﬁned as simvastatin 80 mg, pravastatin 40 mg, lovastatin 80 mg,
ﬂuvastatin 80 mg, atorvastatin 80 mg, rosuvastatin 20–40 mg or maximum statin dose plus ezetimibe 10 mg/day
b The strength of the lipid-lowering treatment in HeFH patients was considered low (lovastatin 10–40 mg, ﬂuvastatin
80 mg, pravastatin 20–40 mg, simvastatin 10–20 mg, atorvastatin 10 mg) in 6.9% of cases, moderate (lovastatin 80 mg,
simvastatin 40 mg, atorvastatin 20–40 mg, rosuvastatin 5–10 mg, simvastatin ? ezetimibe 20 ? 10 mg) in 40% and high
(atorvastatin 80 mg, rosuvastatin 20 mg, simvastatin ? ezetimibe 40 ? 10 mg) in 53%
948 Adv Ther (2015) 32:944–961
Table 2 Lipid-lowering treatments and LDL cholesterol targets in secondary prevention
Study Study size Treatment Control
Acute coronary syndrome (ACS)
[26] N = 4334 Statins: 90.8%
Statins ? ezetimibe: 24.7%
LDLc\70 mg/dl: 14.3%
LDLc\100 mg/dl: 55.7%
[28] N = 1381 LDLc\70 mg/dl: 11% ﬁrst ACS; 14.1%
recurrent ACS
LDLc 70–99 mg/dl: 24.1% ﬁrst ACS;
23.2% recurrent ACS
Coronary heart disease (CHD)
[32] N = 7600 Statins: 80.6% LDLc\100 mg/dl: 26.1%
[33] N = 1452 (5256 visits) Statins: 92.1% LDLc\70 mg/dl: 292 (5.7%)
LDLc 70–100 mg/dl (non DM): 916 (18%)
LDLc 70–100 mg/dl (DM): 640 (12.6%)
LDLc[100 mg/dl: 3244 (63.7%)
[34] N = 1108 Statins: 967 (87.3%); non DM:
678 (85.8%); DM 289 (90.9%)
LDLc\100 mg/dl: 454 (41%); non DM:
301 (38.1%); DM: 153 (48.1%)
[35] N = 7823 Statins: 80.4% LDLc[100 mg/dl: 73.8%
[36] N = 1038 Statins: 82.9%; 82.8%[65 years;
83.1% B65 years
Ezetimibe 17.4%; 16.2%
[65 years; 18.7% B65 years
LDLc\100: 42.4%[65years; 46.5%
B65 years




[38] N = 2024 LDLc\100 mg/dl- BMI 20-24.9: 35.2%;
BMI 25–29.9: 30.5%; BMI C30: 27.9%.
Ischemic stroke
[39] N = 473 LLT: 319 (67.4%)
Statins: 311 (65.8%)
LDLc\100 mg/dl: 33%
[40] N = 955 LLT: 75.5%
Statins: 695 (72.8%)
Ezetimibe: 76 (8%)
LDLc\100 mg/dl: 28.9% of treated
patients
[41] N = 407 LLT: 193 (47.4%):
Statins: 180 (44.2%)
LDLc\100 mg/dl: 101 (24.8%); LDLc
[100 mg/dl: 139 (34.2%); unknown:
167 (41.0%)
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PAD
A very limited number of studies were identified
for this particular subgroup [42, 62–64]. In these
studies, the clinical diagnosis of PAD was based
on an ankle-brachial index \0.9. A prevalence
of hypercholesterolemia between 60% and 80%
was reported. With regard to treatment applied
and results achieved, between 46% and 79% of
patients received LLT. However, only 30% of
them achieved a target LDLc \100 mg/dl




In accordance with a previous diagnosis or the
use of LLT, data indicated that between 50%
Fig. 2 Control in secondary prevention. LDLc low-density lipoprotein cholesterol, DM diabetes mellitus, BMI body mass
index
Table 2 continued
Study Study size Treatment Control
Peripheral arterial disease (PAD)
[42] N = 4087 LLT: 79.1%
Statins: 76.2%
LDLc\100 mg/dl: 30.4%
[43] N = 105 LLT: 45.7%
LLT lipid-lowering treatment, FH familiar hypercholesterolemia, DM diabetes mellitus, LDLc low-density lipoprotein
cholesterol, ACS acute coronary syndrome, CHD coronary heart disease, BMI body mass index
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Table 3 Lipid-lowering treatments and LDL cholesterol targets in primary prevention: diabetes mellitus
Study Study size Treatment Control
[33] N = 1452 (612 DM)
patients; 5256 visits
Statins: 92.1% LDLc\70 mg/dl: 292 (5.7%)
LDLc 70–100 mg/dl non DM: 916
(18%)
LDLc 70–100 mg/dl DM: 640 (12.6%)
LDLc[100 mg/dl: 3244 (63.7%)
[71] N = 3703 (1445 DM) Statins: 100% (during at least
3 months)
LDLc[100 mg/dl: 59.2% of DM
patients
LDLc[100 mg/dl: 44.5% of non DM
patients
[72] N = 1828 (320 DM).
2 visits








Statin ? ezetimibe: 61 (3.3%)
LDLc\100 mg/dl in DM or CVD and
LDLc\115 in high risk patients:
Baseline: All 30.5%; CVD 40.4%; DM
35.8%
Follow up: All 44.7%; CVD 65.3%; DM
50.4%
LDLc\70: CVD 17.9%; DM 16.5%
[26] N = 4402 (1748 DM) Statins: 76.7%:
Statins ? ezetimibe: 18.8%
LDLc[100 mg/dl: 56.9%
LDLc[70 mg/dl: 84.7%
[73] N = 3710 (39% DM) Statins: 100%
Ezetimibe: 17.4%
LDLc[100 mg/dl in high risk or
[120 mg/dl in low risk: 63.1%
CVD (n = 846); LDLc[100 mg/dl:
64.7%
[3] N = 11,544




44.1% of patients aware of
elevated LDLc
23.7% of all patients with
elevated LDLc
LDLc\115 mg/dl (\100 mg/dl DM
and CVD): 40.2% of treated patients
(9.5% of total sample with elevated
LDLc)
LDLc\115 mg/dl (\70 DM and
CVD): 31.3% (7.3%)
% of DM or CVD patients with LDLc
\100 mg/dl: 40.5% or 43.6%, respect
% of DM or CVD patients with LDLc
\70 mg/dl: 7.0% or 5.2% respectively
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and 84% of DM patients would present with
hypercholesterolemia [44, 57, 65–68].
Regarding the rates of LLT usage (Table 3;
Fig. 3), between 45% and 90% of DM patients
were using a LLT [26, 69, 70]. With respect to
the lipid control achieved in this population,
rates ranged from 40% to 50% in DM patients
with no CVD history (LDLc goal \100 mg/dl),
to only 15% in DM patients with a history of
CVD (LDLc goal\70 mg/dl).
Patients with High CV Risk
Within this group of special interest in the
prevention of CVD, between 30% and 60% had
a specific diagnosis of hypercholesterolemia,
based on a TC [200 mg/dl or previous
treatment [1, 3, 76–78].
LLT was used in 50% to 60% of these patients
[1], while control rates ranged from 35% to 65%,
considering a LDLc target of\100 mg/dl [1, 72,
73]. Table 4 and Fig. 4 summarize these data.
Table 3 continued
Study Study size Treatment Control










[68] N = 1177 Statins 48% LDLc\100 mg/dl: 25.6%
[74] N = 4776 (12.5% DM
patients)
In n = 409 DM patients
LDL B100 mg/dl: 45.3%
LDL B70 mg/dl: 11.8%
[66] N = 771 DM Statin: 722 (93.6%)
Ezetimibe: 151 (19.6%)
LDLc[70 mg/dl: 501 (73.4%)
LDLc[100 mg/dl: 243 (31.5%)
[75] N = 2704 (1067 DM) LLT: 1634 (60.4%) LDLc\100 mg/dl in DM or CVD;
\130 mg/dl others: 930 (34.4%)
LDLc\100 mg/dl: 34.7% DM;
34.2% CVD
[76] N = 1748 DM and
CHD
N = 2654 DM without
CHD
LLT: 76.7%
Statin and ezetimibe: 18.8%
LDLc[100 mg/dl: 56.9%
LDLc[70 mg/dl: 84.7%
[69] N = 320 DM Statins: 60% LDLc B100 mg/dl: males 41.7%;
females 39.1%
LLT lipid-lowering treatment, FH familiar hypercholesterolemia, DM diabetes mellitus, CVD cardiovascular disease, LDLc
low-density lipoprotein cholesterol, CHD coronary heart disease
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DISCUSSION
It has been shown that hypercholesterolemia is
significantly present among patients with an
increased vascular risk and those who have
already suffered a CV event: 50–84% of
patients with DM [44, 57, 67, 68, 74], 30–50%
of high risk patient [1, 3, 76–78], and between
35% and above 80% in those with overt CVD,
depending on the type of event [15–41, 44–60].
The association of this condition with the risk of
CV events [9, 83] makes it all the more necessary
to endorse the interventions aimed at managing
the modifiable risk factors (diet and exercise), to
prescribe a LLT accordingly to individual’s CV
risk [7], and also to plan an adequate monitoring
of the pharmacological therapies implemented
to maximize their benefit. There are many
examples of this relationship in our country:
hypercholesterolemia doubled the risk of an
ischemic disease [84, 85], and would be the
cause of 22% of all coronary events. The risk
increased significantly among patients who did
not have their lipid values controlled, while
among those diagnosed with controlled
hypercholesterolemia and, who are undergoing
a lipid-lowering treatment, the increased risk of
ischemic heart disease was not statistically
significant [84].
Due, in large part, to the information above,
the use of lipid-lowering drugs in Spain has
increased from 18.9 defined daily doses (DDD)
per 1000 inhabitants per day (DDD/1000
inhabitants/day) in the year 2000 to 102.6
DDD/1000 inhabitants/day in the year 2012,
an increase of 442% [86]. Statins are the most
commonly used drugs (91.7 DDD/1000
inhabitants/day in 2012) representing 89.3%
of all LLT, but also fibrates, bile-acid
sequestrants, ezetimibe, and omega 3 fatty
acids contributed during 2012 to LLT use [86].
The increase in the use of LLT can be justified by
Fig. 3 Control in primary prevention: diabetes mellitus. LDLc low-density lipoprotein cholesterol, DM diabetes mellitus
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Table 4 Lipid-lowering treatments and LDL cholesterol targets in primary prevention: high cardiovascular risk patients
High or very high cardiovascular risk
Study Study size Treatment Control
[73] N = 3710 (39% DM) Statins: 100%
Ezetimibe: 17.4%
High risk patients (CVD, DM or SCORE
[5%; n = 2574), LDLc[100 mg/dl: 60.7%
SCORE[5% without CVD nor DM
(n = 407), LDLc[100 mg/dl: 83.2%
[72] N = 1828 2 visits At baseline, 1013 (55.4%)
received at least 1 drug:
Statins: 830 (45.4%)
Ezetimibe: 126 (6.9%)




Statin ? ezetimibe: 61 (3.3%)
LDLc levels\100 mg/dl in DM or CVD and
LDLc\115 in high risk patients:
Baseline: All 30.5%; CVD 40.4%; DM 35.8%
Follow up: All 44.7%; CVD 65.3%; DM 50.4%
LDLc\70 mg/dl: CVD 17.9%; DM 16.5%
[79] RCT. 2 arms:
Experimental-EG
(n = 33) Supportive
system to decision
making
Control-CG (n = 44)
Use of High intensity statins:
EG: 74.6%/CG: 25.4%




LDLc\70: 55% GI; 12.5% GC
LDLc\100: 75% GI; 45.8% GC
[80] N = 37 Statins: 100%
Ezetimibe: 10.8%
LDLc\130 md/dl: 43%
[81] N = 222. LLT: 85% LDLc\100 mg/dl: 51.3% of high risk patients
LDLc\70 mg/dl: 7.5% of high risk patients
[77] N = 3716 (15.5%
calibrated-SCORE
[5)




[1] N = 27,903 (n = 9335
with dyslipidemia)
High–very high risk:




LDLc\100 mg/dl in DM or high–very high
risk:\3%
LDLc\100 mg/dl in DM or\130 mg/dl in
moderate to very high risk or\160 mg/dl in
low risk): 46% males, 52% females
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their ability to reduce the risk of CV events, and
the associated burden of disease.
Although treatments available have led to an
improvement in the clinical situation and
prognosis of these cases, it is clear that there is
a lot of effort still to be made until LDLc targets
defined by current European guidelines [7] can
be reached by most of patients. In all of the
groups analyzed, an important number could
still be found with total cholesterol and LDLc
levels above the acceptable threshold. For
example, among diabetics, only between 15%
(in case of those with previous CVD) and
40–50% (in those without CVD) attained
recommended levels of lipids in the blood [26,
69–71], and the situation is not better in
secondary prevention or among patients with
HeFH. This picture, which is similar to other
western countries [87–89], highlights the need
to continue maximizing the control of lipids in
the blood and to minimize therapeutic inertia.
Regarding this, in one recent study with CHD
patients, therapeutic inertia was estimated to be
as high as 73% [33].
It should be noted, as the main limitation of
the present work, how difficult it is to make a
more exact approximation of the estimations
presented in this manuscript. This is due in
great part to the sheer heterogeneity of the
criteria used in the various studies in defining
hypercholesterolemia, CV risk, ACS or CHD. In
addition, one other relevant aspect to consider
is the nature of the studies included. They are
mainly cross-sectional investigations and with a
wide range of different sampling procedures
and sample sizes. Even more, many studies are
based on the analysis of individuals coming
from the same national databases or registries.
Table 4 continued
High or very high cardiovascular risk
Study Study size Treatment Control
[75] N = 2704 LLT: 1634 (60.4%) LDLc\100 mg/dl in DM or CVD;\130 mg/
dl others: 930 (34.4%)
LDLc\100 mg/dl: 34.7% DM; 34.2% CVD
[82] N = 217 Ezetimibe (monotherapy):
42.4%
Ezetimibe ? statins: 43.3%
LDLc\100 mg/dl or 70 mg/dl: 43.8% of high
or very high risk patients
[3] N = 11,544




44.1% of patients aware of
elevated LDLc
23.7% of all patients with
elevated LDLc
LDLc\115 mg/dl (\100 DM and CVD):
40.2% of treated patients (9.5% of total
sample with elevated LDLc)
LDLc\115 mg/dl (\70 DM and CVD):
31.3% (7.3%)
% of DM or CVD patients with
LDLc\100 mg/dl: 40.5% or 43.6%, respect.
% of DM or CVD patients with LDLc
\70 mg/dl: 7.0% or 5.2% respectively
LLT lipid-lowering treatment, FH familiar hypercholesterolemia, DM diabetes mellitus, CVD cardiovascular disease, LDLc
low-density lipoprotein cholesterol, EG experimental group, CG control group
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Considering these important constraints, a
more analytic approach as meta-analysis
might be applied at least with those studies
following comparable clinical criteria to have a
more accurate estimation of disease prevalence
and control in each of the groups of interest,
and to highlight the significance of the
heterogeneity found between studies. Despite
this, an important strength of the present
manuscript is that all the relevant studies
carried out in Spain and published in peer
review journals have been systematically
identify and reviewed to facilitate a global but
comprehensive report of this condition in our
country.
CONCLUSIONS
There is an elevated prevalence of
hypercholesterolemia in Spain among those
selected groups with a high CV risk. Although
LLT is present in an elevated proportion,
controls rates of lipid levels need to be
improved both in primary and secondary
prevention.
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